Short answer
Zenas BioPharma, Inc. (ZBIO) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Zenas BioPharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1, the accompanying press release
Item EX-99.1 · Exhibit EX-99.1
- FDA review of obexelimab IgG4-RD BLA targets May 27, 2027, while EMA validated the MAA, advancing dual-market commercialization
- Cash, equivalents and investments $647.1M, with projected funding through second quarter 2029 assuming $75M milestone and $75M debt draw
- Revenue $10.0M from Bristol-Myers Squibb milestone, but net loss widened to $108.9M from $51.5M
- R&D expense increased to $58.5M and G&A to $27.4M, reflecting expanded trials and pre-commercialization spending
- Key catalysts remain fourth-quarter 2026 SunStone SLE results and ZB021 Phase 1 data, with orelabrutinib Phase 3 MS trials ongoing
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zenas BioPharma, Inc. 8-K filings
Get the next ZBIO 8-K as it lands
Follow ZBIO for push alerts, or ask the research agent what this filing means.